Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04133-z
Abstract: Eculizumab is effective in managing patients with paroxysmal nocturnal hemoglobinuria (PNH). In South Korea, the financial support for eculizumab therapy is extended by the National Health Insurance Services (NHIS) only to patients with high-risk PNH… read more here.
Keywords: group; paroxysmal nocturnal; eculizumab; nocturnal hemoglobinuria ... See more keywords
Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Hematology"
DOI: 10.1007/s12185-020-02934-6
Abstract: Ravulizumab demonstrated noninferior efficacy and comparable safety to eculizumab in two open-label, phase 3 studies in patients with paroxysmal nocturnal hemoglobinuria (PNH) who complement inhibitor-naive (Study 301) or were previously treated with eculizumab (Study 302).… read more here.
Keywords: ravulizumab; study; japanese patients; eculizumab ... See more keywords
Comment on “Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab”
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-020-00950-7
Abstract: After reading the review article by Wijnsma et al. [1] with great interest, we would like to comment on the utility of eculizumab dose monitoring in pregnancy. While Wijnsma et al. describe a strategy for… read more here.
Keywords: comment; comment pharmacology; pharmacology; eculizumab ... See more keywords
Eculizumab: A Review in Generalized Myasthenia Gravis
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0875-9
Abstract: The humanized monoclonal antibody eculizumab (Soliris®) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with… read more here.
Keywords: eculizumab review; generalized myasthenia; eculizumab; myasthenia gravis ... See more keywords
Atypical hemolytic uremic syndrome due to DGKE mutation and response to eculizumab: lessons for the clinical nephrologist
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Nephrology"
DOI: 10.1007/s40620-020-00925-8
Abstract: An 18-month-old white boy presented with non-bloody diarrhea and pallor and one week of cough and nasal congestion. On examination, he was hypertensive (115/99) and tachycardic (140 bpm). Pertinent labs included normocytic hemolytic anemia with… read more here.
Keywords: atypical hemolytic; uremic syndrome; hemolytic uremic; eculizumab ... See more keywords
Hemolytic Uremic Syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Current Treatment Options in Pediatrics"
DOI: 10.1007/s40746-020-00216-1
Abstract: The emergence of specific treatment of atypical hemolytic uremic syndrome (aHUS) using eculizumab has allowed renal function recovery and safe kidney transplantation (KT). Early and precise recognition of complement-mediated (CM) atypical HUS (aHUS) is challenging… read more here.
Keywords: hus; uremic syndrome; treatment; hemolytic uremic ... See more keywords
Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
Sign Up to like & getrecommendations! Published in 2018 at "Transplantation proceedings"
DOI: 10.1016/j.transproceed.2018.02.012
Abstract: Atypical hemolytic-uremic syndrome (aHUS) is an extremely rare disease, and up to 70% of the patients have a genetic mutation in the encoding components of complement activation or anti-complement factor H autoantibodies. The risk of… read more here.
Keywords: eculizumab; eculizumab treatment; hybrid gene; complement factor ... See more keywords
Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria.
Sign Up to like & getrecommendations! Published in 2018 at "Seminars in Hematology"
DOI: 10.1053/j.seminhematol.2018.04.001
Abstract: Abstract Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation in the phosphatidylinositol glycan class A, X-linked gene, responsible for a deficiency in glycosyl phosphatidylinositol-anchored proteins. The absence of one of the glycosyl phosphatidylinositol-anchored protein… read more here.
Keywords: years clinical; paroxysmal nocturnal; eculizumab; experience eculizumab ... See more keywords
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
Sign Up to like & getrecommendations! Published in 2021 at "AJP Reports"
DOI: 10.1055/s-0041-1731057
Abstract: The atypical hemolytic uremic syndrome (aHUS) in the newborn is a rare disease, with high morbidity. Eculizumab, considered a first-line drug in older children, is not approved in neonates and in children weighing less than… read more here.
Keywords: neonatal atypical; atypical hemolytic; uremic syndrome; hemolytic uremic ... See more keywords
P0137FIRST RUSSIAN BOSIMILAR OF ECULIZUMAB IN THE TREATMENT OF AN ADULT PATIENT WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME
Sign Up to like & getrecommendations! Published in 2020 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaa142.p0137
Abstract: The disease diagnostics results and the efficacy of pathogenetic treatment when transferring from the original drug to the biosimilar were evaluated during clinical observation of an adult patient with aHUS. A 46-year-old patient has a… read more here.
Keywords: eculizumab; treatment; treatment adult; adult patient ... See more keywords
Successful Management of a Rare Cause of Hemolytic Uremic Syndrome With Eculizumab in a Child
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000001121
Abstract: Background: Hemolytic uremic syndrome (HUS) is characterized by microangiopathic hemolytic anemia, acute renal failure, and thrombocytopenia. It very rarely coexists with acute lymphoblastic leukemia (ALL) emerging before, simultaneously, or after the diagnosis has been made,… read more here.
Keywords: hemolytic uremic; eculizumab; successful management; uremic syndrome ... See more keywords